265129-71-3 Usage
Uses
Used in Pharmaceutical Research:
GW7647 is used as a PPARα ligand for various applications in pharmaceutical research, including its role in the regulation of lipid homeostasis and the activation of genes involved in fatty acid β-oxidation, binding, and transport.
Used in Defatting Medium:
In the field of cell biology, GW7647 is used as a PPARα ligand in defatting medium to treat primary human hepatocytes, allowing researchers to study its effects on glycolytic function in cardiomyocytes.
Used in Cardiac Cell Therapies:
GW7647 is used as a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ in regenerative cardiac cell therapies, potentially contributing to the development of novel treatments for heart-related conditions.
Used in Cancer Research:
GW7647 is utilized in breast cancer MDA-MB-231 cells to activate PPARs, which may provide insights into the role of PPARα in cancer biology and the development of targeted therapies.
Used in Lipid Metabolism Studies:
GW7647 is employed in research focused on lipid metabolism, as it has been shown to lower triglycerides significantly in fat-fed hamsters and rats, providing a valuable tool for understanding the underlying mechanisms and potential therapeutic applications.
Biological Activity
Potent and highly selective PPAR α agonist (EC 50 values are 6, 1100 and 6200 nM for human PPAR α , PPAR γ and PPAR δ receptors respectively). Modulates oleate metabolism and mitochondrial enzyme gene expression in mature myotubules in vitro . Has lipid-lowering effects following oral administration in vivo .
Biochem/physiol Actions
GW7647 reduces serum triglyceride levels and enhances hepatic expression of genes associated with β-oxidation. Usage of GW7647 along with metformin in conditions of liver steatosis or injury improves the enzymatic levels of aspartate transaminase (AST) and alanine transaminase (ALT) in serum.
Check Digit Verification of cas no
The CAS Registry Mumber 265129-71-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,5,1,2 and 9 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 265129-71:
(8*2)+(7*6)+(6*5)+(5*1)+(4*2)+(3*9)+(2*7)+(1*1)=143
143 % 10 = 3
So 265129-71-3 is a valid CAS Registry Number.
InChI:InChI=1/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)
265129-71-3Relevant articles and documents
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
-
, (2008/06/13)
Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer, and for the treatment of Alzheimer's disease in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-α agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.
Chemical compounds
-
, (2008/06/13)
Novel compounds of Formula (1) and esters, salts, and physiologically functional derivatives thereof are disclosed. Methods for preparing and using the compounds are also disclosed. Many of these compounds are selective activators of PPAR alpha. The compo
